TPO and autoimmune thrombocytopenic purpura: As a result of data from these randomized clinical studies, romiplostim (as well as other TPO-RAs) is generally recommended in guidelines for children with ITP who fail on first-line therapy, including in those with ITP < 1 year from diagnosis.